New and effective treatment of experimentally induced venous thrombosis with anti-inflammatory rPSGL-Ig

Thromb Haemost. 2002 Mar;87(3):374-82.

Abstract

Background: P-selectin antagonism decreases thrombosis and inflammation in animal models of venous thrombosis (VT) prophylaxis. This study defines results using a P-selectin receptor antagonist for VT treatment.

Methods: Eight juvenile baboons underwent 6 h of iliofemoral venous stasis to produce an occlusive VT. Two days later, animals were treated for 14 days with rPSGL-Ig, 4 mg/kg (n3), LMWH (n2) or saline (n3) and treatment continued weekly (rPSGL-Ig) or daily (LMWH, saline). The animals were examined and sacrificed 14 days after treatment initiation (n4) or on day 90 (n4).

Results: Percent spontaneous vein reopening revealed a significant increase (p <0.05) in the proximal iliac vein in rPSGL-Ig and LMWH animals compared to controls (62%, 70% vs 8%), without differences in inflammation. No anticoagulation, thrombocytopenia, or wound complications were found in rPSGL-Ig animals. At 90 days, recanalization with iliac vein valve competence was found in treated animals.

Conclusions: rPSGL-Ig successfully treated established VT without anticoagulation.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Chemokines / metabolism
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Heparin, Low-Molecular-Weight / administration & dosage
  • Iliac Vein / drug effects
  • Iliac Vein / metabolism
  • Iliac Vein / pathology
  • Inflammation / pathology
  • Male
  • Membrane Glycoproteins / administration & dosage*
  • Papio
  • Treatment Outcome
  • Venous Thrombosis / complications
  • Venous Thrombosis / drug therapy*

Substances

  • Anti-Inflammatory Agents
  • Chemokines
  • Heparin, Low-Molecular-Weight
  • Membrane Glycoproteins
  • P-selectin ligand protein